

1 RSV healthcare burden in adults before and since the 2 emergence of the COVID-19 pandemic in 6 European 3 countries

4 Arantxa Urchueguía-Fornes^{*1,2}, Richard Osei-Yeboah^{*3}, Ombeline Jollivet⁴, Caroline Klint Johannesen^{5,6}, Toni
5 Lehtonen⁷, Michiel van Boven^{8,9}, David Gideonse⁸, Rachel A. Cohen¹⁰, Alejandro Orrico-Sánchez^{1,2,11}, Rolf
6 Kramer⁴, Thea K. Fischer⁶, Terho Heikkinen¹², Harish Nair³, Harry Campbell³, for the PROMISE investigators

7 8 Affiliations

9 1 Vaccine Research Department, Foundation for the Promotion of Health and Biomedical Research in the
10 Valencian Region (FISABIO), Valencia, Spain
11 2 CIBER de Epidemiología y Salud Pública, Instituto de Salud Carlos III
12 3 Centre for Global Health, Usher Institute, The University of Edinburgh, Edinburgh, United Kingdom
13 4 Sanofi, Lyon, France
14 5 Department of Virus and Microbiological Special Diagnostics, Statens Serum Institut, Copenhagen, Denmark
15 6 Department of Clinical Research, North Zealand University Hospital, Capital Region, Denmark
16 7 Department of Health Security, Finnish Institute for Health and Welfare, Helsinki, Finland
17 8 Centre for Infectious Disease Control, National Institute for Public Health and the Environment, the
18 Netherlands
19 9 Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University,
20 Utrecht, the Netherlands
21 10 GSK, Rockville, Maryland, United States
22 11 Catholic University of Valencia, Valencia, Spain
23 12 Department of Pediatrics, University of Turku and Turku University Hospital, Turku, Finland
24

25 *Shared first authorship

26 **PROMISE investigators:** Harish Nair (University of Edinburgh), Hanna Nohynek (THL), Anne Teirlinck (RIVM),
27 Louis Bont (University Medical Center Utrecht), Peter Openshaw (Imperial College London), Andrew Pollard
28 (University of Oxford), Veena Kumar (Novavax), Elizabeth Begier (Pfizer), Jim Janimak (GlaxoSmithKline),
29 Jenny Hendrix (Janssen), Ainara Mira-Iglesias and Javier Díez-Domingo (FISABIO-Public Health), Rolf Kramer
30 (Sanofi Pasteur), Eva Molero (Teamit).

31 Corresponding author

32 Richard Osei-Yeboah, PhD

33 Centre for Global Health, Usher Institute, The University of Edinburgh, 5-7 Little France Drive, BioQuarter
34 Gate 3 - Edinburgh, EH16 4UX, United Kingdom.

35 Email: Richard.Osei-Yeboah@ed.ac.uk

36 Alternate Corresponding author

37 Arantxa Urchueguía-Fornes, PhD

38 Vaccine Research Department, Foundation for the Promotion of Health and Biomedical Research in the
39 Valencian Region (FISABIO), Valencia, Spain

40 Email: arantxa.urchueguia@fisabio.es

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

41 **Abstract**

42

43 Introduction:

44 Respiratory Syncytial Virus (RSV) is a major cause of morbidity in older adults. With the emergence
45 of the coronavirus disease 2019 (COVID-19) and the subsequent changes in respiratory viral
46 circulation, it is crucial to reassess RSV-associated healthcare burden in adults. This study assessed
47 RSV-associated healthcare burden in adults in six European countries before and during the COVID-
48 19 pandemic.

49

50 Methods:

51 We conducted a retrospective analysis using national hospital admissions data from Denmark,
52 England, Finland, the Netherlands, Scotland, and regional surveillance data from the Valencia
53 region (Spain). We included patients aged ≥ 18 years hospitalised for respiratory tract infections
54 (RTIs) from 2016 to 2023. We assessed RSV-coded and laboratory-confirmed hospitalisations,
55 intensive care unit (ICU) admissions, in-hospital length of stay (LOS), and mortality.

56

57 Results:

58 RSV-associated hospitalisations significantly reduced during the 2020/2021 season across all
59 countries, coinciding with strict COVID-19 preventive measures, but resurged in subsequent
60 seasons. We observed the highest hospitalisation rates in adults aged ≥ 85 years. RSV-coded
61 hospitalisations were found to underestimate the true burden when compared with laboratory-
62 confirmed cases. Underestimation factors ranged from 1.1 to 4.3 times across countries. No
63 significant differences were observed in LOS or ICU admission rates for RSV-associated
64 hospitalisations compared to RTIs.

65 Discussion:

66 Our findings underscore the complex epidemiology of RSV in older adults. The differences between
67 RSV-coded and laboratory-confirmed cases highlight the critical need for improved surveillance and
68 diagnostic practices to better assess the true burden. Our findings could be vital for guiding public
69 health strategies, particularly with the recent introduction of RSV vaccines for older adults.

70 **Keywords:** Respiratory syncytial virus; burden; adults; hospitalisation; surveillance; mortality; ICU
71 admissions

72 **Collaborators**

73 **PROMISE investigators:** Harish Nair (University of Edinburgh), Hanna Nohynek (THL), Anne Teirlinck (RIVM),
74 Louis Bont (University Medical Center Utrecht), Peter Openshaw (Imperial College London), Andrew Pollard
75 (University of Oxford), Veena Kumar (Novavax), Elizabeth Begier (Pfizer), Jim Janimak (GlaxoSmithKline),
76 Jenny Hendrix (Janssen), Ainara Mira-Iglesias and Javier Díez-Domingo (FISABIO-Public Health), Rolf Kramer
77 (Sanofi Pasteur), Eva Molero (Teamit).

78

79

80

81 **Ethical statement**

82 All countries participating in this study received ethical and/or institutional board approvals to
83 access and utilise national and/or regional health registries.

84

85 **Funding statement**

86 This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking
87 under grant agreement 101034339. This Joint Undertaking received support from the European
88 Union's Horizon 2020 research and innovation programme and EFPIA. The funding source organised
89 the collaboration and received final report on the project. The funding source had no influence of
90 the scientific content of the project.

91 **Data availability**

92 All data are presented in this manuscript. Written requests may be made to the relevant data
93 controllers to access specific national or regional data.

94

95 **Acknowledgements**

96 We thank the peripheral diagnostic laboratories spread throughout the Netherlands and the Health
97 iQ Limited, trading as CorEvitas, which has a data sharing agreement in place with NHS Digital to
98 store a copy of the latest 5 years of Hospital Episode Statistics data in-house and provided England
99 data. Authorised Health iQ employees accessed to this in-house database to identify which the
100 study population and conduct data aggregation. Copyright © (2023), re-used with the permission of
101 The Health & Social Care Information Centre. All rights reserved.

102 We acknowledge the support of the electronic data research and innovation services (eDRIS) team
103 at Public Health Scotland for their involvement in obtaining approvals, provisioning and linking, and
104 the use of the secure analytical platform with the National Safe Haven.

105 **Conflict of interest**

106 AUF, MvB, TL, and DG report no conflicts of interest. ROY reports a research contract from
107 AstraZeneca. CKJ reports a research grant from Nordsjællands Hospital, travel grants from the
108 University of Copenhagen, William Demants Fond in Denmark, and the European Society of Clinical
109 Virology and expert consultation fees from Sanofi outside of the submitted work. OJ and RK are
110 Sanofi employees and may hold stock shares. RAC is an employee of GSK and holds financial
111 equities in GSK shares. AOS has attended several congresses whose registration, travel, and
112 accommodation costs were covered by MSD, GSK, AZ, and Sanofi Pasteur (SP). TKF reports
113 honoraria for panel participation and conference presentation from GSK and Pfizer with 100% own
114 decision on content. TH reports payment or honoraria from Pfizer for lecture at an academic
115 meeting and participation in Ad hoc advisory board meeting for Pfizer. HN reports personal fees
116 from Pfizer, GSK, Sanofi, Novavax and Merck. HC reports grants from NIHR Global Health Unit
117 funding and Baszucki Brain Research Foundation, consulting fees from WHO (Geneva), membership
118 of academic / educational committees of RSE, Acad MedSci, and UK Research Excellence
119 Framework outside the submitted work.

120 **Authors' contributions**

121 OJ, AUF, CKJ, TL, DG, RAC, RK, TH, TKF, MvB, ROY, HN, and HC contributed to the design of the
122 study. OJ, AUF, CKJ, TL, MvB, RAC, and ROY contributed to the data extraction for this work and
123 contributed to the analysis of the data, OJ and AUF contributed to the data visualization and
124 statistical analyses, AUF and ROY wrote the manuscript, all authors reviewed and validated this
125 manuscript.

126

127 **Introduction**

128 The impact of respiratory syncytial virus (RSV) in older adults is less understood than in young children.
129 Recent findings show higher hospitalisation rates than previously acknowledged, particularly among adults
130 with underlying health conditions, immunocompromised or of advanced age [1-8]. RSV can exacerbate
131 conditions such as asthma, chronic obstructive pulmonary disease (COPD) or heart failure, leading to severe
132 outcomes, such as pneumonia, myocardial infarction or death [9, 10]. Still, accurately determining the true
133 incidence of RSV-related hospitalisations in older adults is challenging due to a lack of routine RSV testing
134 and dedicated surveillance systems and case definitions [11-14].

135 With the recent approvals of RSV vaccines for adults ≥ 60 years of age (Arexvy – GSK, mRESVIA-Moderna and
136 Abrysvo™ - Pfizer) [15-17], accurate RSV burden estimates to assist in immunisation strategies and monitor
137 the vaccines' impact and effectiveness have become a public health priority. The coronavirus disease 2019
138 (COVID-19) pandemic and associated non-pharmaceutical interventions (NPIs) had significant short-term
139 impacts in lowering some respiratory viral circulations [18, 19]. This reduction is known to have had impact
140 RSV epidemiology including healthcare burden [20, 21]. RSV returned in 2021 and 2022 after COVID-19
141 measures were lifted, but the patterns of RSV return varied across geographies (e.g., out-of-season peaks,
142 year-round hospitalisations).

143 This study provides direct estimates of RSV healthcare burden in adults ≥ 18 years, by estimating changes in
144 frequency and burden of RSV-associated illnesses before and since the COVID-19 pandemic (from 2016 to
145 2023) in six European countries: Denmark, England, Finland, the Netherlands, Scotland, and the Spain-
146 Valencia region, as part of the PROMISE (Preparing for RSV Immunisation and Surveillance in Europe)

147 initiative [22]. We present findings on RSV-coded and laboratory-confirmed RSV hospitalisation rates, in-
148 hospital length of stay (LOS), RSV intensive care unit (ICU) admissions, and RSV mortality data. We compare
149 admission rates across countries and age groups and provide estimates before and during the COVID-19 era.

150

151 **Methods**

152 **Study design**

153 A retrospective study of all-cause respiratory tract infection (RTI) admissions, RSV-coded admissions and RSV
154 laboratory-confirmed admissions using routinely collected hospital admissions data from five countries
155 (Denmark, England, Finland, the Netherlands, and Scotland) and a hospital-based active surveillance network
156 in one country (Spain-Valencia region).

157 **Study population**

158 National hospital registries containing individual-level patient data on hospital admissions of patients ≥ 18
159 years were used for Denmark, England, Finland, the Netherlands, and Scotland. In Spain-Valencia, data from
160 a regional prospective hospital-based active surveillance network was used [23, 24] (see Supplementary
161 Methods). Hospital admissions of patients ≥ 18 years with any mention of RTI using ICD-9-CM or ICD-10
162 codes (full list available in Supplementary Material) were extracted in Denmark, England, Finland, the
163 Netherlands, and Scotland. In Spain-Valencia, all hospital admissions for individuals aged ≥ 18 years, arriving
164 through the emergency room, meeting preliminary inclusion criteria (i.e., residents of the catchment area,
165 not institutionalised and not hospitalised in the previous 30 days) and complying with the influenza-like
166 illness (ILI) [25]) case definition were included (see Supplementary Methods).

167 **Study period**

168 The study period covered full calendar years from 2016/17 to 2022/23; country-specific available study
169 periods are described in the Supplementary Methods. A year was defined starting from ISO week 27 of one

170 given year to ISO week 26 of the following year. In Spain-Valencia, data were adjusted to the RSV circulation
171 period to allow comparisons across years with different lengths of the active monitoring period
172 (Supplementary Methods). A calendar year is referred to from here on as season.

173

174 **Outcomes**

175 Hospital admissions were included if lasting more than 12 hours (8 hours in Spain-Valencia, any duration for
176 England). Scheduled or routine admissions, as well as re-admissions within 28 days (30 days in Spain-
177 Valencia) for the same diagnosis, were excluded. The following hospital admission types were defined: 1)
178 RTI-coded admissions, identified by any ICD-9-CM or ICD-10 code related to a respiratory tract infection (full
179 list of codes in Supplementary Methods) 2) RSV-coded admissions defined as any RTI admission including an
180 RSV-associated ICD-9-CM or ICD-10 code (4801, 46611, 0796, J12.1, J20.5, J21.0, B97.4). 3) RSV-confirmed
181 admissions, where a positive RSV polymerase chain reaction (PCR) test was performed within -7 to +2 days
182 of the hospitalisation (data available only in Denmark, Finland, Scotland, and Spain-Valencia).

183 A hospital admission was considered completed upon hospital discharge or death. In England, data on ICU
184 admissions were also available. Mortality data (available in England, Finland and Spain-Valencia) included
185 any death during or after hospitalisation where the primary or secondary causes of death included one of
186 the diagnoses described in the Supplementary Methods. For deaths occurring post-discharge (Finland only),
187 those that occurred 14 days after the end of the hospitalisation were excluded. Hospitalisation types were
188 further classified by the following diagnosis groups: upper respiratory tract infection (URTI), lower
189 respiratory tract infection (LRTI) stratified by bronchitis & bronchiolitis, pneumonia & influenza, severe acute
190 respiratory syndrome coronavirus 2 (SARS-CoV-2) or unspecified LRTI (Supplementary Methods).

191

192 **Data analysis**

193 Data from patients aged ≥ 18 years were analysed and stratified by the following age groups: 18-64, 18-49
194 (only in Finland and Scotland, in Finland denominators were not available for this age group), 50-64 (only in
195 Finland, Scotland, and Spain-Valencia, in Finland no population data available for this age group), 65-74, 75-
196 84 and ≥ 85 years. Age was calculated as the person's age at the time of each hospitalisation. Due to data
197 privacy compliance, Denmark, Finland, the Netherlands, and Scotland provided approximate counts when
198 numbers were between 1-4, setting them to 2. Admission numbers were calculated by hospitalisation type,
199 age group, diagnosis group, country, and season, and further stratified by COVID-19 period. We defined
200 before COVID-19 admissions as the average (\pm SD) of all admissions between 2016/17-2018/19 (2017/18-
201 2018/19 for England and Scotland) and during COVID-19 as the average (\pm SD) of all admissions between
202 2021/22-2022/23 (2021/22 only for Denmark and Scotland). For the COVID-19 stratification, we excluded
203 admissions from seasons 2019/20-2020/21, as they were not considered representative seasons due to the
204 strong NPI measures in place. During season 2019/20, 37,462 RTI admissions were coded as SARS-COV-2 in
205 England, 1,351 in Finland, 11,105 in the Netherlands and 3,791 in Scotland (*data not shown*), hence this
206 season was excluded from the before COVID-19 group in all countries.

207 ICU admission and in-hospital case fatality rates were calculated using the corresponding hospitalisation
208 numbers as denominators. The in-hospital LOS in days was estimated from admission and discharge dates. It
209 included the ICU stay or the transfer to another hospital, if any. LOS median and interquartile ranges were
210 calculated by hospitalisation type, age group, diagnosis, country, and season.

211 Admission rates and 95% confidence intervals (CIs) per 100,000 person-years for RSV-coded and RSV-
212 confirmed hospitalisations were calculated by age group, country and season using population data as of
213 January 01 (Denmark, Finland, the Netherlands, and Spain-Valencia) or mid-year (England, Scotland). The
214 95% CIs were estimated using a Poisson exact method. In Spain-Valencia, the population was multiplied by
215 the RSV circulation duration in years to account for seasonal differences in active monitoring periods
216 (Supplementary Methods). In Scotland and England, no population data for the 2022/23 season was
217 available, so the population was assumed to be as the 2021/22 population. An average (\pm SD) of hospital

218 admission rates was calculated over the whole study period for each age group and country, and further
219 stratified by COVID-19 period. To understand RSV-coding practices, we divided RSV-confirmed admission
220 rates by the corresponding RSV-coded rates for each country, season and age group when enough sample
221 size was available (≥ 10 patients).

222 Data collection was standardised using common data collection templates and definitions. Country-specific
223 data challenges prevented the use of a general definition for some of the outcomes (detailed in
224 Supplementary Methods). All analyses were performed in R (version 4.3.1) using common programming
225 scripts to ensure comparability despite healthcare systems heterogeneity.

226

227 Results

228 Table 1 shows the average (\pm SD) ≥ 18 years population among all seasons, together with the total number of
229 RTI, and the total number and proportion of RSV-coded and RSV-confirmed admissions among adults ≥ 18
230 years during the whole study period.

231 **Table 1 Average population and admission number among patients 18 years of age and above.** The average
232 ≥ 18 years population (\pm SD) during the whole study period is shown for each country. The total number of ≥ 18 years RTI
233 admissions and the total number (and proportion from the RTI admissions) of RSV-coded and RSV-confirmed
234 admissions are shown per country.

Country	Study period	Average Population (\pm SD)	N RTI	N RSV-coded (%)	N RSV-confirmed (%)
Denmark	2017/18-2021/22	4,652,883 ($\pm 47,104$)	23,523	477 (0.2%)	1,393 (0.6%)
England	2017/18-2022/23	44,321,027 ($\pm 360,008$)	4,305,867	21,587 (0.5%)	NA
Finland	2016/17-2021/22	4,479,585 ($\pm 35,360$)	337,751	5,078 (1.5%)	6,259 (1.9%)
Netherlands	2016/17-2020/21	13,951,809 ($\pm 182,643$)	47,574	4,633 (1%)	NA
Scotland	2016/17-2021/22	4,431,017 ($\pm 23,027$)	272,105	1,185 (0.4%)	2,057 (0.8%)
Spain-Valencia	2016/17-2022/23*	378,995 ($\pm 51,303$)	8,752	48 (0.5%)	442 (5.1%)

235 *Except 2020/21

236 The yearly average study population ranged from 378,995 (Spain-Valencia) to 44,321,027 (England). The
237 total number of RTI admissions ranged from 8,752 (Spain-Valencia) to 4,305,867 (England). The proportion
238 of RSV-coded admissions ranged from 1.5% (Finland) to 0.2% (Denmark). Among countries with available
239 laboratory-confirmed data, RSV-confirmed proportions ranged from 5.1% (Spain-Valencia) to 0.6%
240 (Denmark). Overall numbers and proportions stratified by COVID-19 periods are available in Supplementary
241 Table S1. Numbers and proportions of admissions by age group, country, diagnosis group and COVID-19
242 stratification are available in Supplementary Table S2. Most of the RSV admissions were classified as
243 Pneumonia (Supplementary Figure S1).

244

245 **RSV admission rates by season, country, and age group**


246 RSV-coded hospitalisation rates per 100,000 person-years varied by country, age group and the COVID-19
247 period. For adults aged 18-64 years, average rates (\pm sd) ranged from 0.6 (\pm 0.2, Denmark) to 4.7 (\pm 3.4,
248 Finland) before COVID-19 and from 1.1 (\pm 1.1, Spain-Valencia) to 4.8 (\pm 2.4, Finland) during COVID-19. For
249 adults aged 65-74 years, rates ranged from 0 (\pm 0, Spain-Valencia) to 25 (\pm 23, Finland) before COVID-19 and
250 from 5.1 (\pm NA, Denmark) to 25 (\pm 14, Finland) during COVID-19. Among those aged 75-84 years, rates were
251 between 6 (\pm 2.7, Denmark) and 66 (\pm 64.3, Finland) before COVID-19 and between 13 (\pm NA, Denmark) and
252 45 (\pm 26, Finland) during COVID-19. For adults aged \geq 85 years, rates varied from 7.3 (\pm 7.5, Spain-Valencia) to
253 166 (\pm 154, Finland) before COVID-19 and from 20 (\pm NA, Denmark) to 116 (\pm 64.4, Finland) during COVID-19
254 (Figure 1A, Supplementary Figure S2, Supplementary Figure S4A, Supplementary Table S3). The highest RSV-
255 coded admission rates were observed in Finland, followed by England. Denmark and Spain-Valencia showed
256 the lowest rates, likely due to data collection methods (ILI restriction in Spain-Valencia) , RSV coding
257 practices [26] or low number of diagnosis codes recorded at discharge in Spain-Valencia.

258 RSV-confirmed admission rates per 100,000 person-years also varied substantially across countries, age
259 groups and COVID-19 era. For adults aged 18-64 years, average lab-confirmed rates (\pm sd) ranged from 1.8 (\pm
260 0.3, Denmark) to 7 (\pm 2.9, Spain-Valencia) before COVID-19 and from 2 (\pm 1.7, Scotland) to 6 (\pm 3, Finland)

261 during COVID-19. For adults aged 65-74 years, rates were between 10 (\pm 3, Denmark) and 45 (\pm 21, Spain-
262 Valencia) before COVID-19 and between 6 (\pm 6, Spain-Valencia) and 29 (\pm 17, Finland) during COVID-19. For
263 those aged 75-84 years, rates ranged from 20 (\pm 7, Denmark) to 148 (\pm 46, Spain-Valencia) before COVID-19
264 and from 25 (\pm 24, Scotland) to 54 (\pm 31, Finland) during COVID-19. Among adults aged \geq 85 years, rates
265 varied from 44 (\pm 24, Denmark) to 260 (\pm 105, Spain-Valencia) before COVID-19 and from 51 (\pm 57, Scotland)
266 to 127 (\pm 81, Finland) during COVID-19 (Figure 1B, Supplementary Figure S3, Supplementary Figure S4B,
267 Supplementary Table S5). The highest RSV-confirmed admission rates were observed in Finland and Spain-
268 Valencia. In Spain-Valencia, all included ILI patients were systematically tested for RSV, but in Finland, testing
269 denominators were not known.

270 A drop in RSV admission rates was observed across all countries and age groups during the 2020/21 season.
271 The incidence of RSV-coded or RSV-confirmed admissions ranged between 0 and 1.6 per 100,000 in 2020/21
272 considering all countries and age groups (Figure 1, Supplementary Figures S2-S3, and Supplementary Tables
273 S3-S4, with rates returning to pre-pandemic levels from 2021/22 onwards. (Figure 1, Supplementary Tables
274 S3- S4, and Supplementary Figures S2-S4). In England, a higher incidence of RSV-coded admissions was
275 observed after 2020/21 (Supplementary Figure S4) across all age groups, but no laboratory-confirmed data
276 were available to see whether the same trend was observed on RSV-confirmed hospitalisations. This trend
277 was also observed in Denmark with both coded and lab-confirmed admissions without strong evidence, as
278 only one season during COVID-19 was available and the error bars before COVID-19 overlap with the during
279 COVID-19 bars (Supplementary Figure S4).

280 In some countries (Finland, Spain-Valencia), high RSV admission rates in a given year were often followed by
281 lower rates the next year, as previously described in some EU countries (Finland, Norway and Denmark) [5].
282 This pattern was also seen across some age groups in Denmark before COVID-19 seasons (Figure S3). A high
283 variability in rates was observed between countries, age groups and seasons, but rates consistently
284 increased with increasing age regardless of the use of coded, lab-confirmed data, country or season
285 (Supplementary Figure S5).



286

287 **Figure 1 Hospitalisation admission rates (95%CI) in patients 18 years of age and above.** The hospital
 288 admissions rates per 100,000 persons-year (y-axis) and season (x-axis) are shown for each country (colour), age group
 289 (vertical subpanels) and hospitalisation type: A) RSV-coded and B) RSV admissions with a laboratory-confirmed result
 290 for RSV. Note that each panel has a different y-axis scale to allow for readability. A summary figure with identical y-axis
 291 scales for all age groups can be found as Supplementary Figure S5.


292

293 **RSV-coding practices**

294 In countries with both RSV-coded and RSV-confirmed data, we estimated the degree of underestimation of
 295 RSV admission rates when relying solely on RSV codes. Denmark, Finland and Scotland had both types of
 296 data available and enough sample size (more than 10 RSV-coded admissions). In these countries, regardless
 297 of the age group and season, RSV-coded admissions resulted in an underestimation of the burden compared
 298 to RSV-confirmed admissions, except in 2021/22 in the ≥ 85 years age group in Finland (Figure 2 and
 299 Supplementary Figures S6-S7). In Finland, the average underestimation factor when relying on ICD-codes for
 300 admission rate estimations was 1.3 (± 0.1) times before COVID-19 and 1.2 (± 0.1) times during COVID-19. In
 301 Scotland, the average underestimation factor was 1.8 (± 0.2) times before COVID-19 and 1.5 (± 0.2) times
 302 during COVID-19. Denmark showed the highest underestimation factor, with an average underestimation

303 factor of 3.5 (± 0.6) times before COVID-19 and 2.5 (± 0.4) times during COVID-19. A figure including
304 admissions of less than 10 patients in the ICD-coded dataset is available as Supplementary Figure S7.

305



306


307 **Figure 2 RSV-coding practices and its underestimation.** The RSV-coded underestimation factor (y-axis) has been
308 obtained by dividing in each season (x-axis), country (vertical subpanels) and age group (horizontal subpanels) the
309 corresponding RSV-confirmed admission rate by the corresponding RSV-coded admission rate. Numbers above the
310 white line indicate that the incidence estimated with RSV-coded admissions is lower than the one estimated with RSV-
311 confirmed. Groups with less than 10 patients in the RSV-coded dataset have been removed in this Figure. A complete
312 picture including >10 patient's group is available in Supplementary Figure S7.

313

314 Length of stay of RSV-associated hospitalisations

315 Figure 3 displays the median length of stay (LOS) for each hospitalisation type, age group, season and
316 country. The median LOS for an RSV admission (RSV-coded or confirmed) with enough sample size (>10
317 patients) ranged between 2.0 days (2017/18, Scotland) to 8.0 days (2017/18, Spain-Valencia) in the 18-64
318 years age group, between 2.0 days (2017/18, Scotland) to 8.0 days (2016/17, Netherlands) in the 65-74 year
319 age group, 1 day (2019/20, Scotland) to 12.5 days (2020/21, England) in the 75-84 years age group and 1 day
320 (2019/20, Scotland) to 9.5 (2021/22, England) in the ≥ 85 years age group. The lowest LOS were always

322 evident within each age group, except in Scotland and England, where a longer LOS was noted in some age
 323 groups during 2020/21 for both RSV-coded and RSV-confirmed admissions, but these were not statistically
 324 significant (Figure 3). The variability between seasons was higher for RSV-coded/confirmed hospitalisations
 325 compared to RTI admissions, but the number of admissions used for the LOS estimations was higher for RTI
 326 admissions. RSV-related hospitalisations did not result in longer stays compared to general RTI admissions
 327 (Supplementary Figure S8).



329 **Figure 3 Hospitalisations median length of stay.** Median LOS (y-axis) and 25/75 quartiles (shadow area) of all
 330 hospital admissions per country, age group and seasons (x-axis). Each hospitalisation type is shown with a different
 331 colour (green: RTI admissions, orange: RSV-coded and violet – RSV-confirmed admissions). If the estimate is based on
 332 less than 10 patients the shape is represented as a dot, whereas if the estimate is based on more than 10 patients the
 333 shape is represented as a triangle. Outliers (18-64 age group and RSV-coded in Spain-Valencia: 52 days [1 patient] and
 334 65-74 age group and RSV-confirmed in Scotland [2 patients]: 18 days) are not shown to allow for readability of the
 335 graph.

336

337 RSV-associated ICU-admissions

338 In England, ICU admissions were available and are summarised in Table 2. Across all age groups, a higher ICU
 339 admission proportion among RSV-coded patients was observed before the COVID-19 pandemic. The ICU

340 admission proportion decreased with increasing age both before and during COVID-19. Before COVID-19, in
341 the 18-64- and 65-74-years age groups, the RSV-coded ICU admission proportions were higher than the
342 overall RTI admission proportions (7.2% versus 5.8% and 7.9% versus 6.1%, respectively). This trend has not
343 been observed since COVID-19. Numbers stratified by diagnosis group are available in Supplementary Table
344 S4.

345 **Table 2.** Average (\pm SD) RTI and RSV-associated ICU admissions in England of the seasons before COVID-19 (2016/17-
346 2018/19) and of the seasons during COVID-19 (2021/22-2022/23) stratified by age group. The proportion of RTI/RSV-
347 coded ICU admissions to the total number of RTI or RSV-coded admissions is also shown.

Age group	COVID-19	Avg. (\pm SD) RTI-ICU admissions, %	Avg. (\pm SD) N RSV-coded ICU admissions, %
18-64	Before	12468 (\pm 292), 5.8%	65 (\pm 23), 7.2%
	During	10318 (\pm 5387), 3.8%	47 (\pm 7), 3.0%
65-74	Before	7372 (\pm 332), 6.1%	46 (\pm 7), 7.9%
	During	4939 (\pm 2275), 3.8%	22 (\pm 3), 2.1%
75-84	Before	6338 (\pm 193), 3.7%	27 (\pm 11), 3.9%
	During	3716 (\pm 1380), 1.9%	12 (\pm 4), 0.9%
\geq 85	Before	1996 (\pm 97), 1.2%	5 (\pm 0), 0.9%
	During	882 (\pm 254), 0.5%	5 (\pm 1), 0.4%

348

349 RSV-associated case fatality rates (CFR)

350 In countries with available mortality data (England, Finland and Spain-Valencia), the CFR among RSV-coded
351 hospitalisations ranged from 0-3.3% before COVID-19 and 0-3.5% during COVID-19 for the 18-64 years age
352 group, 0-7.4% before COVID-19 and 0-8.2% during COVID-19 for the 65-74 years age group, 5.7-12.9% before
353 COVID-19 and 0-10.8% during COVID-19 for the 75-84 years age group, and 11.9-30% before COVID-19 and
354 6.2-17.6% during COVID-19 for the \geq 85 years and older age group (Table 3). Among RSV-confirmed
355 hospitalisations (Finland and Spain-Valencia, respectively), the CFR was 2.5 and 0% before COVID-19, and 1
356 and 0% during COVID-19 for the 18-64 years age group, 3.5 and 5.3% before COVID-19 and 2.2 and 0%
357 during COVID-19 for the 65-74 years age group, 6.5 and 2.4% before COVID-19 and 3.4 and 0% during
358 COVID-19 for the 75-84 years age group, and 12 and 11% before COVID-19 and 6 and 15% during COVID-19
359 for the \geq 85 years age group (Table 3). Numbers stratified by diagnosis group are available in Supplementary
360 Table S5.

162
163

Table 3. Average (\pm SD) RTI and RSV-associated admissions that end up in death in England, Finland and Spain-Valencia of the seasons before COVID-19 (2016/17-2018/19) and of the seasons during COVID-19 (2021/22-2022/23) stratified by age group. The CFR to the total number of RTI or RSV-coded/confirmed admissions is also shown.

Age group	COVID-19	England		Finland			Spain-Valencia		
		Avg. N RTI deaths, CFR	Avg. N RSV-coded deaths, CFR	Avg. N RTI deaths, CFR	Avg. N RSV-coded deaths, CFR	Avg. N RSV-confirmed deaths, CFR	Avg. N RTI deaths, CFR	Avg. N RSV-coded deaths, CFR	Avg. N RSV-confirmed deaths, CFR
18-64	Before	8391 (\pm 232), 3.9%	30 (\pm 1), 3.3%	481 (\pm 25), 3.7%	4 (\pm 3), 2.8%	5 (\pm 4), 2.5%	6 (\pm 3), 1.2%	0 (\pm 0), 0%	0 (\pm 0), 0%
	During	10550 (\pm 1368), 3.9%	54 (\pm 42), 3.5%	402 (\pm 227), 3.5%	1 (\pm 1), 0.6%	2 (\pm 0), 1%	2 (\pm 0), 0.7%	0 (\pm 0), 0%	0 (\pm 0), 0%
65-74	Before	12660 (\pm 612), 10.4%	43 (\pm 3), 7.4%	995 (\pm 28), 8.6%	7 (\pm 8), 4%	8 (\pm 10), 3.5%	13 (\pm 2), 3.3%	0 (\pm 0), 0%	1 (\pm 2), 5.3%
	During	14282 (\pm 1039), 10.9%	86 (\pm 71), 8.2%	958 (\pm 408), 9.2%	4 (\pm 2), 2%	4 (\pm 4), 2.2%	4 (\pm 2), 2.5%	0 (\pm 0), 0%	0 (\pm 0), 0%
75-84	Before	24388 (\pm 1705), 14.1%	54 (\pm 14), 7.8%	1910 (\pm 143), 12.2%	13 (\pm 14), 5.7%	20 (\pm 23), 6.5%	27 (\pm 9), 5.0%	0.3 (\pm 0.7), 12.9%	1 (\pm 1), 2.4%
	During	28196 (\pm 26), 14.6%	152 (\pm 148), 10.8%	1736 (\pm 687), 11.5%	7 (\pm 7), 3.5%	8 (\pm 8), 3.4%	9 (\pm 4), 4.1%	0 (\pm 0), 0%	0 (\pm 0), 0%
\geq 85	Before	34054 (\pm 3645), 19.8%	69 (\pm 20), 11.9%	2559 (\pm 163), 17.8%	30 (\pm 27), 12.3%	38 (\pm 42), 12.3%	48 (\pm 22), 9.7%	0.3 (\pm 0.7), 30%	4 (\pm 1), 11.12%
	During	35145 (\pm 878), 19.7%	219 (\pm 238), 17.6%	2110 (\pm 797), 16.6%	12 (\pm 9), 6.2%	12 (\pm 11), 6.2%	12 (\pm 4), 5.6%	0.5 (\pm 0.5), 12.5%	2 (\pm 2), 15%

364 Discussion

365 This study highlights the complex epidemiology of RSV in adults across several European countries,
366 particularly in the context of the COVID-19 pandemic. The comparison of RSV-coded versus RSV-confirmed
367 hospitalisations reveals significant discrepancies, highlighting challenges in capturing the true burden of RSV-
368 related illnesses. Our data, encompassing multiple countries with varied healthcare systems, provide
369 valuable insights into RSV epidemiological trends. Notably, the study reveals consistent patterns of RSV
370 circulation and age-specific hospitalisation rates despite differing national health practices, suggesting a
371 broader applicability of the findings. This consistency is particularly relevant given the varying public health
372 measures in place during the study period, including NPIs aimed at curbing COVID-19.

373 Across all countries the highest hospitalisation rate was observed in adults aged ≥ 85 years with up to 445
374 laboratory-confirmed hospitalisations per 100,000 person-years. During 2020/21, when the strongest
375 COVID-19 NPI measures were in place, almost no RSV-associated hospitalisations occurred. No significant
376 differences in the LOS of RSV-associated hospitalisations compared to all-cause RTI admissions were
377 observed. Both RSV-associated ICU-admissions and RSV CFRs showed no significant differences compared to
378 RTI ICU-admissions and RTI CFRs. RSV and RTI CFRs increased with increasing age and ICU-admissions
379 decreased with increasing age (Table 2 and Table 3).

380 Country-specific nuances were observed with England, Finland, the Netherlands, and Scotland displaying
381 similar RSV-coded admission trends. This likely reflects similarities in healthcare systems and coding
382 practices. Biennial peaks of RSV admissions were noted in Finland, Spain-Valencia and Denmark, consistent
383 with previous observations [27]. Higher incidences of RSV-confirmed admissions were seen in countries with
384 robust access to laboratory data (Finland and Spain-Valencia, in the latter systematic PCR testing was
385 performed in all included patients). Yet, it is worth noting that diagnostic tests and systematic testing there
386 still may be an underestimation of at least 2.2 times [28, 29].

387 In routinely collected healthcare records, access to laboratory test results is often not possible, and even
388 when available, the testing denominators are commonly not provided. Thus, RSV-coding practices become
389 the best available proxy for estimating RSV burden. A study in Denmark showed that ICD-coded admissions
390 underestimate the true RSV burden [26]. Here, we also observed that relying on RSV codes led to
391 underestimation factors between 1.1 times (Finland) and 4.3 times (Denmark). Finland showed a high
392 correlation between RSV-coded and RSV-confirmed admissions (Pearson $r^2=0.99$), reflecting high quality
393 clinical practices. Yet, similar patterns between RSV-coded and RSV-confirmed admissions were observed in
394 Scotland, Finland, and Denmark, suggesting that, despite its limitations, RSV-coded admissions could be used
395 as an indicator of RSV epidemiology when laboratory data are unavailable [27].

396 RSV epidemiology in older adults appears to be stabilising to pre-COVID-19 patterns, contrasting with the
397 increases observed in paediatric populations [18, 30, 31], due to an immunity debt hypothesis [32] /an
398 increase in RSV testing [33]. In England, a higher rate of RSV-coded admissions was observed during COVID-
399 19, but only two seasons data was used and the trend was not significant (Supplementary Figure S8). Our
400 data included up to three seasons before COVID-19 and two during-COVID-19, which included season
401 2021/22, where NPI measures were still in place in most countries [34]. This may have impacted the
402 estimates. Future data on RSV-related hospitalisations in older adults are needed to fully understand during-
403 COVID-19 trends.

404 The data collection method in Spain-Valencia differed as it relied on an active surveillance network setup for
405 influenza surveillance and on the ILI case definition, which is well-known to underestimate the real RSV
406 burden [11, 14, 35]. Moreover, data in each season was adjusted to the RSV circulation period and the
407 admission rates were shown per 100,000 adults during the RSV circulation period. Despite this, similar
408 trends in seasonality, rates, and age distribution of RSV-confirmed cases were observed between Finland
409 and Spain-Valencia (RSV-confirmed datasets Pearson $r^2=0.75$). This suggests that routinely collected national
410 healthcare data can still provide valuable insights into RSV trends and epidemiology in older adults despite
411 limitations.

412 Our study presents several limitations that must be considered when interpreting the findings. The reliance
413 on routinely collected national healthcare data introduces potential biases, including coding inaccuracies and
414 inconsistencies in clinical practices across different countries. Particularly, the ICD-coded admissions likely
415 underestimate the true burden of RSV, as evidenced by underestimation factors ranging from 1.1 times in
416 Finland to 4.3 times in Denmark. The disparity in coding practices, especially during COVID-19, and the
417 incomplete understanding of RSV testing practices further complicates the analysis and interpretations. The
418 variability in data collection methods and the limited scope of laboratory-confirmed cases restrict direct
419 comparability across countries. These limitations underscore the need for more systematic and standardised
420 testing approaches to improve the accuracy and reliability of RSV burden estimates. The use of other
421 approaches for RSV-burden estimation such as time series modelling [36] could help in overcoming some of
422 these limitations.

423 Despite these limitations, this study provides a comprehensive overview of RSV-associated hospitalisations
424 in adults across multiple European countries, offering critical insights into RSV epidemiology in the context of
425 the COVID-19 pandemic. The observed stabilisation of RSV patterns in older adults post-COVID-19 contrasts
426 with increases seen in paediatric populations, raising questions about age-specific immunity and the impact
427 of NPIs. Despite the inherent limitations related to coding practices and variability in data collection
428 methods, the observed trends are indicative of the significant public health burden posed by RSV in older
429 adults. The introduction of new RSV immunisation strategies underscores the necessity for reliable
430 epidemiological data to guide public health policies and interventions. As such, this study lays the
431 groundwork for future research and surveillance efforts aimed at mitigating the impact of RSV, particularly in
432 the context of evolving viral dynamics and public health landscapes.

433

434

435 **References**

- 436 1. Lee N, Lui GCY, Wong KT, Li TCM, Tse ECM, Chan JYC, et al. High Morbidity and Mortality in Adults
437 Hospitalized for Respiratory Syncytial Virus Infections. *Clin Infect Dis*. 2013;57(8):1069-77.
- 438 2. Nguyen-Van-Tam JS, O'Leary M, Martin ET, Heijnen E, Callendret B, Fleischhackl R, et al. Burden of
439 respiratory syncytial virus infection in older and high-risk adults: a systematic review and meta-analysis of
440 the evidence from developed countries. *European Respiratory Review*. 2022;31(166):220105.
- 441 3. Shi T, Denouel A, Tietjen AK, Campbell I, Moran E, Li X, et al. Global Disease Burden Estimates of
442 Respiratory Syncytial Virus-Associated Acute Respiratory Infection in Older Adults in 2015: A Systematic
443 Review and Meta-Analysis. *J Infect Dis*. 2020;222(Suppl 7):S577-S83.
- 444 4. Nam HH, Ison MG. Respiratory syncytial virus infection in adults. *BMJ*. 2019;l5021.
- 445 5. Falsey AR, McElhaney JE, Beran J, Van Essen GA, Duval X, Esen M, et al. Respiratory Syncytial Virus
446 and Other Respiratory Viral Infections in Older Adults With Moderate to Severe Influenza-like Illness. *The*
447 *Journal of Infectious Diseases*. 2014;209(12):1873-81.
- 448 6. Falsey AR, Criddle MC, Walsh EE. Detection of respiratory syncytial virus and human
449 metapneumovirus by reverse transcription polymerase chain reaction in adults with and without respiratory
450 illness. *J Clin Virol*. 2006;35(1):46-50.
- 451 7. Tseng HF, Sy LS, Ackerson B, Solano Z, Slezak J, Luo Y, et al. Severe Morbidity and Short- and Mid- to
452 Long-term Mortality in Older Adults Hospitalized with Respiratory Syncytial Virus Infection. *The Journal of*
453 *Infectious Diseases*. 2020;222(8):1298-310.
- 454 8. Belongia EA, King JP, Kieke BA, Pluta J, Al-Hilli A, Meece JK, et al. Clinical Features, Severity, and
455 Incidence of RSV Illness During 12 Consecutive Seasons in a Community Cohort of Adults ≥60 Years Old.
456 *Open Forum Infectious Diseases*. 2018;5(12).
- 457 9. Guan XR, Jiang LX, Ma XH, Wang LF, Quan H, Li HY. Respiratory Syncytial Virus Infection and Risk of
458 Acute Myocardial Infarction. *The American Journal of the Medical Sciences*. 2010;340(5):356-9.
- 459 10. Blackburn R, Zhao H, Pebody R, Hayward A, Warren-Gash C. Laboratory-Confirmed Respiratory
460 Infections as Predictors of Hospital Admission for Myocardial Infarction and Stroke: Time-Series Analysis of
461 English Data for 2004–2015. *Clinical Infectious Diseases*. 2018;67(1):8-17.
- 462 11. Sáez-López E, Pechirra P, Costa I, Cristóvão P, Conde P, Machado A, et al. Performance of
463 surveillance case definitions for respiratory syncytial virus infections through the sentinel influenza
464 surveillance system, Portugal, 2010 to 2018. *Eurosurveillance*. 2019;24(45).
- 465 12. Allen KE, Chommanard C, Haynes AK, Erdman DD, Gerber SI, Kim L. Respiratory syncytial virus testing
466 capabilities and practices among National Respiratory and Enteric Virus Surveillance System laboratories,
467 United States, 2016. *J Clin Virol*. 2018;107:48-51.
- 468 13. Drews SJ, Branche AR, Falsey AR, Lee N. What is the role of rapid molecular testing for seniors and
469 other at-risk adults with respiratory syncytial virus infections? *J Clin Virol*. 2019;117:27-32.
- 470 14. Amodio E, Belluzzo M, Genovese D, Palermo M, Pisciotta V, Vitale F. What 'case definition' for
471 respiratory syncytial virus infection? Results of a systematic literature review to improve surveillance among
472 the adults. *J Pub Health*. 2024(fdac066):1-9.
- 473 15. Wise J. First RSV vaccine for older adults is approved in Europe. *BMJ*. 2023;381:p978.
- 474 16. Kingwell K. RSV vaccines score landmark FDA approvals. *Nat Rev Drug Discov*. 2023;22(7):523-5.
- 475 17. Melgar M, Britton A, Roper LE, Talbot HK, Long SS, Kotton CN, et al. Use of Respiratory Syncytial
476 Virus Vaccines in Older Adults: Recommendations of the Advisory Committee on Immunization Practices —
477 United States, 2023. *Morb Mortal Wkly Rep*. 2023;72(29):793-801.
- 478 18. Cong B, Koç U, Bandeira T, Bassat Q, Bont L, Chakhunashvili G, et al. Changes in the global
479 hospitalisation burden of respiratory syncytial virus in young children during the COVID-19 pandemic: a
480 systematic analysis. *The Lancet Infectious Diseases*. 2023.

- 481 19. Tang JW, Bialasiewicz S, Dwyer DE, Dilcher M, Tellier R, Taylor J, et al. Where have all the viruses
482 gone? Disappearance of seasonal respiratory viruses during the COVID-19 pandemic. *J Med Virol.*
483 2021;93(7):4099-101.
- 484 20. Angoulvant F, Ouldali N, Yang DD, Filser M, Gajdos V, Rybak A, et al. Coronavirus Disease 2019
485 Pandemic: Impact Caused by School Closure and National Lockdown on Pediatric Visits and Admissions for
486 Viral and Nonviral Infections—a Time Series Analysis. *Clin Infect Dis.* 2021;72(2):319-22.
- 487 21. Britton PN, Hu N, Saravanos G, Shrapnel J, Davis J, Snelling T, et al. COVID-19 public health measures
488 and respiratory syncytial virus. *Lancet Child Adolesc Health.* 2020;4(11):e42-e3.
- 489 22. PRomISE. Preparing for RSV Immunisation and Surveillance in Europe 2021 [04 March 2024].
490 Available from: <https://imi-promise.eu>.
- 491 23. Mira-Iglesias A, Demont C, López-Labrador FX, Mengual-Chuliá B, García-Rubio J,
492 Carballido-Fernández M, et al. Role of age and birth month in infants hospitalized with RSV-confirmed
493 disease in the Valencia Region, Spain. *Influenza and Other Respiratory Viruses.* 2022;16(2):328-39.
- 494 24. Puig-Barberà J, García-De-Lomas J, Díez-Domingo J, Arnedo-Pena A, Ruiz-García M, Limón-Ramírez R,
495 et al. Influenza Vaccine Effectiveness in Preventing Influenza A(H3N2)-Related Hospitalizations in Adults
496 Targeted for Vaccination by Type of Vaccine: A Hospital-Based Test-Negative Study, 2011–2012 A(H3N2)
497 Predominant Influenza Season, Valencia, Spain. *PLoS ONE.* 2014;9(11):e112294.
- 498 25. Commission Implementing Decision (EU) 2018/ 945. Decisions. Official Journal of the European
499 Union. 2018:L170/1 - L/74.
- 500 26. Egekvov-Cavling AM, Johannesen CK, Lindegaard B, Fischer TK. Underreporting and misclassification
501 of RSV-coded hospitalization among adults in Denmark between 2015/16 to 2017/18. *J Infect Dis.* 2023.
- 502 27. Reeves RM, Van Wijhe M, Tong S, Lehtonen T, Stona L, Teirlinck AC, et al. Respiratory Syncytial Virus-
503 Associated Hospital Admissions in Children Younger Than 5 Years in 7 European Countries Using Routinely
504 Collected Datasets. *J Infect Dis.* 2020;222(Supplement_7):S599-S605.
- 505 28. Li Y, Kulkarni D, Begier E, Wahi-Singh P, Wahi-Singh B, Gessner B, et al. Adjusting for Case Under-
506 Ascertainment in Estimating RSV Hospitalisation Burden of Older Adults in High-Income Countries: a
507 Systematic Review and Modelling Study. *Infect Dis Ther.* 2023;12(4):1137-49.
- 508 29. Onwuchekwa C, Moreo LM, Menon S, Machado B, Curcio D, Kalina W, et al. Underascertainment of
509 Respiratory Syncytial Virus Infection in Adults Due to Diagnostic Testing Limitations: A Systematic Literature
510 Review and Meta-analysis. *J Infect Dis.* 2023;228(2):173-84.
- 511 30. Abu-Raya B, Viñeta Paramo M, Reicherz F, Lavoie PM. Why has the epidemiology of RSV changed
512 during the COVID-19 pandemic? *eClinicalMedicine.* 2023;61:102089.
- 513 31. Esparza-Miranda LA, Juarez-Tobias S, Munoz-Escalante JC, Oliva-Jara UA, Cadena-Mota S, Wong-
514 Chew RM, et al. Clinical and Epidemiologic Characteristics of Infants Hospitalized with Respiratory Syncytial
515 Virus Infection During the 2022-2023 Season in Mexico. *Pediatr Infect Dis J.* 2023;42(10):e382-e4.
- 516 32. Chan CM, Wahab AA, Ali A. Assessing the impact of COVID-19 on epidemiological changes of severe
517 pediatric respiratory syncytial virus infections in Malaysia. *Frontiers in Public Health.* 2024;12.
- 518 33. Petros BA, Milliren CE, Sabeti PC, Ozonoff A. Increased Pediatric Respiratory Syncytial Virus Case
519 Counts Following the Emergence of Severe Acute Respiratory Syndrome Coronavirus 2 Can Be Attributed to
520 Changes in Testing. *Clin Infect Dis.* 2024.
- 521 34. Heemskerk S, Spreeuwenberg P, Nair H, Paget J. Comparison of the Oxford COVID-19 Government
522 Response Tracker and the ECDC-JRC Response Measures Database for nonpharmaceutical interventions.
523 *Influenza Other Respi Viruses.* 2024;18(1).
- 524 35. Korsten K, Adriaenssens N, Coenen S, Butler CC, Verheij TJM, Bont LJ, et al. World Health
525 Organization Influenza-Like Illness Underestimates the Burden of Respiratory Syncytial Virus Infection in
526 Community-Dwelling Older Adults. *J Infect Dis.* 2022;226(Supplement_1):S71-S8.
- 527 36. Johannesen CK, Van Wijhe M, Tong S, Fernández LV, Heikkinen T, Van Boven M, et al. Age-Specific
528 Estimates of Respiratory Syncytial Virus-Associated Hospitalizations in 6 European Countries: A Time Series
529 Analysis. *J Infect Dis.* 2022;226(Supplement_1):S29-S37.

